Media coverage about medical benefits of MDMA and ketamine affects perceived likelihood of engaging in recreational use

Abstract

Background

Research on the efficacy of ketamine in treating depression and 3,4-methylenedioxymethamphetamine (MDMA) in treating post-traumatic stress disorder have been widely covered by the media. Given recent widespread coverage of the efficacy of these drugs, it is important to determine whether such coverage influences prevalence of recreational use. While longitudinal studies would be most ideal for assessing this, to acquire preliminary data, we tested survey items assessing this potential phenomenon in a population known for high prevalence of use of these drugs.

Method

Adults entering randomly selected nightclubs in New York City (n = 209) were surveyed about drug use. Questions were included to assess their perceived likelihood of recent media coverage about medical benefits associated with use of ketamine and MDMA affecting their own use.

Results

Two-thirds (66.8%) of participants had ever used ecstasy/MDMA and 22.6% had ever used ketamine. The plurality of participants reported that media coverage about ketamine (46.1%) and MDMA (39.9%) did not affect their likelihood of using. 10.1% and 21.0% of participants reported increased likelihood of using ketamine and MDMA, respectively. 52.3% of those reporting past-month ketamine use and 6.1% of those reporting no lifetime use reported being more likely to use in response to media coverage about ketamine. 28.6% of those reporting past-month ecstasy use and 5.5% of those reporting no lifetime use reported being more likely to use in response to media coverage about MDMA.

Discussion

Media coverage about the medical benefits of ketamine and MDMA might influence specific subsets of people to use.

Keywords:

• Ketamine
• MDMA
• media
• nightlife
• club drugs
• intention to use

Disclosure statement

The authors declare no conflict of interest.

Ethical approval

This study was approved by the authors' institutional review board and all participants provided informed consent before participating.

Additional information

Funding

This work was supported by the National Institute on Drug Abuse (R01DA044207).